Pro Medicus stock
Price history
−22.33% over the period1 year: from $251.14 (November 18, 2025) to $195.06 (November 18, 2026), −22.33%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 18, 2026 | $195.06 |
| October 30, 2026 | $196.20 |
| September 30, 2026 | $163.92 |
| August 31, 2026 | $179.39 |
| July 31, 2026 | $162.21 |
| June 30, 2026 | $203.43 |
| May 29, 2026 | $132.26 |
| April 30, 2026 | $134.40 |
| March 31, 2026 | $116.90 |
| February 27, 2026 | $130.00 |
| January 30, 2026 | $184.12 |
| December 31, 2025 | $220.87 |
| November 28, 2025 | $266.54 |
| November 18, 2025 | $251.14 |
At a glance
The company
Provides medical imaging software and services including radiology information systems, enterprise imaging platforms, and mobile applications to healthcare facilities
Latest results
Quarter to June 30, 2026 · EPS $0.90 (estimate $0.69)
TickerLandia's take on Pro Medicus
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 77 vs a median of 116 over its last 10 fiscal years.
- Strong point: Profitability (98/100 in its group). Weak point: Dividend (32/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−28.51% from the 52-week high
Analysts · 15 analysts
Average target$203.21+4.18% vs. price
Buy 9 · Hold 5 · Sell 1 · Buy
TickerLandia Fingerprint: Pro Medicus
Compared with similar companies: very high profitability, very high price, and very high financial strength.
Financials and price compared with 44 companies in related industries (health_services), worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricevery high97
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 105.9 96 Forward P/E 85.8 96 P/E (trailing 12 months) 79.4 99 Price/book 46.7 96 Price/sales 80.5 97 Profitabilityvery high98
How much it earns on revenue and capital.
Metric Value Position in group ROE 75.0% 94 ROA 25.8% 99 Gross margin 99.8% 99 Operating margin 74.9% 99 Net marginabove 100%: likely one-off items 101.4% 99 Earnings stabilitylow37
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.1% 15 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 59 Growthvery high83
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +48.40% 81 Revenue growth (year over year) +18.20% 81 Average revenue growth (3 years) +27.96% 88 Financial strengthvery high94
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 6.85 97 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.73 91 Debt/equitycounts in reverse: lower means more financial strength 0.00 94 Dividendlow32
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 0.3% 13 Payout ratio 27.2% 36 Consecutive dividend years 15 years 47 Market momentumstrong64
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +1.23% 49 Relative strength (6 months) +48.79% 96 Distance from 200-day average +21.82% 94 1-year return −22.33% 17 Riskhigh70
How much the price swings.
Metric Value Position in group Volatility (60 days) 36.8% 51 Beta (1 year) 1.21 74 Maximum drawdown (12 months) 59.4% 86
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Pro Medicus is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2026), Pro Medicus's P/E today is 76.9, below the median of its last 10 fiscal years (116.5; between 59.1 and 258.9 from 2017 to 2026). Pro Medicus's Forward P/E: 85.8, +194% against the median of a group of 5 similar companies (29.2).
Compared with 5 similar companies
| Metric | Pro Medicus | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 85.8 | Middle | |
| Operating margin | 74.9% | High | |
| ROE | 75.0% | High | |
| Debt/equity | 0.00 | Low | |
| Price/book | 46.7 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Pro Medicus. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$136.91M
Latest quarter · Q2 2026
Net income
$94.12M
Latest quarter · Q2 2026
Quarterly net margin
68.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $21.07B
- P/E
- 79.4
- EPS
- $2.54
- Volume
- 158.61K
- Daily trading
- €26.93M
- Dividend yield
- 0.35%
- Last ex-dividend on September 7, 2026
How Pro Medicus is changing
All resultsRevenue grew 30.9% a year on average over the last 5 years
Operating margin rose from 67.3% to 74.9%
Free cash flow equal to 69% of net income
Returns
Pro Medicus returns with dividends
$1,000 invested in Pro Medicus 5 years ago, on November 18, 2021, would be worth $3,224 today with dividends reinvested: +222.35% in total, +26.38% per year. On price alone it would be $3,164 (+216.40%).
| Period | Pro Medicus | S&P/ASX 200 | $1,000 becomes |
|---|---|---|---|
| 1 month | +9.81% | +0.42% | $1,098 |
| 6 months | +55.40% | +4.44% | $1,554 |
| Year to date | −11.69% | +1.94% | $883 |
| 1 year | −21.96% | +4.89% | $780 |
| 3 years | +123.81% | +25.85% | $2,238 |
| 5 years | +222.35% | +20.38% | $3,224 |
| 10 years | +4,142.28% | +65.75% | $42,423 |
Over the last 6 months it has done better than 87% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P/ASX 200: price only. Calculate your investment
The chart in detail
Pro Medicus: technical analysis
Pro Medicus is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 41.0% below its all-time closing high ($330.48, July 17, 2025).
- Trend
- Upward
- RSI (14 sessions)
- 52
- Between 30 and 70
- vs 200-session average
- +21.82%
Support and resistance
Price areas where Pro Medicus has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$210.20+7.76%2 touches, last on August 21, 2026
- Last price$195.06
- Support$169.18−13.27%4 touches, last on September 18, 2026
- Support$153.79−21.16%3 touches, last on October 5, 2026
- Support$140.64−27.90%2 touches, last on May 5, 2026
Volatility and risk
Over the last year it has moved more than the S&P/ASX 200.
- Beta (1 year) vs S&P/ASX 200
- 1.21
- Volatility (60 sessions, annualised)
- 36.8%
- Largest fall in the last year
- −59.45%
In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Pro Medicus: seasonality
Average monthly price change over 26 years
Over the last 26 years, the strongest month for Pro Medicus has been November: +7.50% on average, positive in 19 years out of 26. The weakest has been February: −3.17% on average, positive in 12 years out of 26.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.05% | −2.49% | 12 of 26 |
| February | −3.17% | −2.19% | 12 of 26 |
| March | −1.02% | −0.76% | 11 of 26 |
| April | +4.49% | +3.25% | 15 of 26 |
| May | +1.25% | −1.21% | 10 of 26 |
| June | −0.89% | −0.88% | 12 of 26 |
| July | +6.52% | +4.77% | 19 of 26 |
| August | +7.10% | +7.54% | 19 of 26 |
| September | −0.10% | −1.21% | 12 of 26 |
| October | +5.07% | +0.18% | 13 of 26 |
| November | +7.50% | +7.47% | 19 of 26 |
| December | +2.83% | +0.33% | 13 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Pro Medicus and its competitors
Sales of medical imaging software reach customers in Australia, Europe and North America, where the company supplies software and services to hospitals and healthcare organisations. Its core offering is Visage RIS, a radiology information system covering patient registration, billing, scheduling, reporting and integration with picture archive and communication systems, alongside Visage 7, an imaging platform that lets radiologists, physicians and clinicians view 2-D, 3-D and 4-D images.
- Headquarters
- Richmond, Australia
- Employees
- 153
- Founded
- 1983
- Chief executive
- Sam Hupert
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Pro MedicusPME | $14.19B | 74.9% | 79.4 | +55.40% |
| M32413 | $7.64B | 19.5% | 26.5 | +28.11% |
| XtalPi Holdings2228 | $3B | -124.6% | — | −35.62% |
| 4DMedical4DX | $933.07M | -813.7% | — | −47.12% |
| Tempus AITEM | $11.81B | -18.5% | — | +44.39% |
| DoximityDOCS | $5.85B | 27.1% | 45.5 | +64.00% |
Same industry or related industries, similar size. Compare Pro Medicus with its competitors · Full profile
